About Us

For researchers on the frontiers of single-cell biology, Cytobank provides a cloud­-based storage and analysis solution optimized for high­-parameter workflows. Cytobank enhances research productivity by enabling scientists in biopharmaceutical companies and academia to:

  • Explore multiple hypotheses simultaneously
  • Automatically secure, organize, annotate, and preserve source data for fast and efficient confirmation and compliance
  • Securely collaborate with colleagues across disciplines and geographies
  • Tap into Cytobank’s deep expertise in single-cell technologies


Cytobank’s founders are leaders in their fields, with landmark papers in cell signaling and cytometry.
David Craford

David Craford, President and CEO

David has more than 25 years of experience in the life sciences industry with a proven track record for building new markets and establishing market leadership. Prior to joining Cytobank, David was CCO at Pathwork Diagnostics, a genomics-­based cancer test developer and clinical lab. Before this he was vice president of business development at Affymetrix, Inc., where he held various business development and marketing leadership roles during the company’s growth. Early in his career, David held senior sales roles at Amersham Life Sciences, Inc., and BTX, a life sciences instrumentation company. David received a B.A. in Biochemistry and Cell Biology from the University of California, San Diego, and an MBA with a focus on marketing and finance from the Haas School of Business at the University of California, Berkeley.

Jonathan Irish

Jonathan Irish, Ph.D., CSO and Co-founder

Jonathan’s focus is working to combine computational biology techniques with basic research into human immunology and genetics in order to understand why cancer patients’ cells resist existing therapies. Jonathan received his Ph.D. from the Cancer Biology program at Stanford University while working in Dr. Garry Nolan’s lab. He was honored as a James H. Clark Fellow and as a G.J. Lieberman Fellow for his doctoral thesis on leukemia cell signaling and leadership in the Stanford community. He continued his postdoctoral studies in Dr. Ronald Levy’s lab at Stanford University, where he used clinical signaling profiles to identify a novel type of therapy-­resistant cancer cell present in aggressive tumors. He has been a Fellow of the Leukemia and Lymphoma Society and is an NIH/NCI Pathway to Independence K99/R00 Awardee (2009–2015). His research group at Vanderbilt University uses single-cell system biology tools such as mass cytometry (CyTOF) to study how signaling networks govern healthy development and drive human diseases.

Angela Landrigan

Angela Landrigan, Ph.D., Director of Products

Angela is passionate about building analytics tools to accelerate the field of immuno-oncology. She enjoys empowering teams to build robust but easy-to-use tools that link high-level, scalable views to underlying raw data. Prior to joining Cytobank, she was a National Science Foundation Graduate Research Fellow while co-mentored by Dr. Paul J. Utz and Dr. Ronald Levy in the Stanford University Immunology Program, where she was awarded a NIH U19 pilot grant during her Ph.D. studies and postdoctoral fellowship. During these studies, she discovered of a novel pathway by which T cells are activated, and characterized the response of cancerous T cells to immunotherapy agents. Prior to that, her research focused on functional RNA in the lab of David Liu during her undergraduate career at Harvard University.

Katherine Drake

Katherine Drake, Ph.D., Director of Informatics

Katherine enjoys empowering scientists to use and understand complex machine learning algorithms that power discovery. Her work focuses on the development of data processing, machine learning and statistical inference pipelines to provide objective insight into complex biological problems. Prior to joining Cytobank, her work at the clinical test development companies Gensignia Life Sciences and Prometheus Laboratories focused on the development of multi-marker predictive models for disease outcomes in lung cancer and inflammatory bowel disease. Katherine received her Ph.D. in Pharmaceutical Science and Pharmacogenomics at the University of California, San Francisco, and her M.S. in Epidemiology from the University of California, Berkeley. At UCSF, she worked in the lab of Dr. Esteban Burchard studying genetic and clinical epidemiology of pediatric asthma in admixed populations. During this time, she discovered ancestry-associated rare genetic variation that contributes to the differential response to albuterol in these populations.